(UroToday.com) The American Urologic Association (AUA) annual meeting included a late-breaking abstract session with a presentation by Dr. Laurence Klotz discussing results of the Sentinel® Prostate Cancer Platform, a test for stratification of prostate cancer risk groups. The miR Sentinel® PCC4 Test measures the expressions of 442 small non-coding RNAs extracted from urinary exosomes to differentiate patients with no molecular evidence of prostate cancer from those with molecular evidence of prostate cancer. The test further classifies men with molecular evidence of prostate cancer into low-, intermediate- or high-risk disease. At the AUA meeting, Dr. Klotz and colleagues presented the results of their study comparing the miR Sentinel® PCC4 Test to systematic core needle biopsy in men presenting with initial suspicion of prostate cancer.